Mucopolysaccharidosis Type Ii clinical trials

Explore recruiting mucopolysaccharidosis type ii clinical trials.

Recruiting mucopolysaccharidosis type ii studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Mucopolysaccharidosis Type Ii trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2/3, Multicenter, Double-Blind, Randomized Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic or Non-Neuronopathic Mucopolysaccharidosis Type II

Belgium, Netherlands, Germany, France, Italy, Czechia +2 more

Phase II and Phase III (Integrated) EU CTIS Study details

An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in Mucopolysaccharidosis Type II (Hunter Syndrome) Subjects

France, Spain, Germany, Poland, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-Label Extension to Investigate the Long-Term Safety, Tolerability, and Efficacy of DNL310 in Patients With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

Italy, Belgium, Sweden, Spain, Czechia, Germany +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A PHASE III STUDY OF JR-141 IN MUCOPOLYSACCHARIDOSIS TYPE II (HUNTER SYNDROME) PATIENTS

Italy, Spain, Germany, Poland, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1/2, Multicenter, Open-Label Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL310 in Pediatric Participants with Hunter Syndrome

Netherlands

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Mucopolysaccharidosis Type Ii trials by city

Mucopolysaccharidosis Type Ii in Toronto Mucopolysaccharidosis Type Ii in Vancouver Mucopolysaccharidosis Type Ii in Montreal Mucopolysaccharidosis Type Ii in Calgary Mucopolysaccharidosis Type Ii in Edmonton Mucopolysaccharidosis Type Ii in Ottawa Mucopolysaccharidosis Type Ii in Winnipeg Mucopolysaccharidosis Type Ii in Quebec City Mucopolysaccharidosis Type Ii in Hamilton Mucopolysaccharidosis Type Ii in Kitchener Mucopolysaccharidosis Type Ii in London Mucopolysaccharidosis Type Ii in Halifax Mucopolysaccharidosis Type Ii in New York Mucopolysaccharidosis Type Ii in Los Angeles Mucopolysaccharidosis Type Ii in Chicago Mucopolysaccharidosis Type Ii in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease